Free expedited shipping US board certified clinicians, all 50 states 24/7 unified patient care HSA · FSA eligible Compounded in the USA
← Living Vitality
Trellis Vitality NAD+

Why NAD+ Injections Sting — and What Actually Changes It

If your NAD+ injection burns, that is common — and it is not evidence the medication is working, or that something has gone wrong. The likely drivers are pH, volume and rate, and all three are modifiable.

Cover art: Why NAD+ Injections Sting — and What Actually Changes It

If your NAD+ injection burns, that is common, it is not evidence the medication is working, and it is not evidence that something has gone wrong. The most likely contributors are the acidity of the solution, the volume being delivered into the tissue, and how quickly it is pushed — all three of which are modifiable. What follows is the mechanism as the pharmacology currently supports it, what a clinician can adjust, and the one category of injection reaction that is a reason to stop and call someone rather than adjust technique.

Why would an injection sting in the first place?

Injection-site pain is a well-studied problem in pharmacology, and the drivers are reasonably well characterised. A 2019 review of the factors influencing pain at subcutaneous injection sites identifies formulation pH as one of the strongest predictors, and recommends formulating close to physiological pH — around 7.4 — to reduce pain, irritation and tissue damage (Usach et al. 2019). The same review points to osmolality, noting that isotonic preparations near 300 mOsm/kg are the target and that values well above that carry a higher risk of pain.

The clearest demonstration of the pH effect comes from local anaesthetics, where it has been tested directly. A Cochrane systematic review of 23 randomised trials found that adjusting the pH of lidocaine upward, toward physiological, reduces pain on injection (Cepeda et al. 2010). An independent systematic review reached the same conclusion (Davies 2003). Lidocaine is not NAD+, and no trial has tested buffering in NAD+ specifically — but the underlying tissue mechanism is not drug-specific. An acidic solution placed into subcutaneous tissue provokes a nociceptive response.

Is NAD+ acidic?

In its raw form, yes. Nicotinamide adenine dinucleotide free acid dissolved in water at 10 g/L has a reported pH of 2.5 to 3.0 at 20°C, per the manufacturer’s product specification (Sigma-Aldrich). That is meaningfully below physiological pH.

Here is where we have to be careful, and where most of what is written on this subject overreaches. No published source gives the pH of a finished, compounded NAD+ injectable as it is actually dispensed to a patient. A compounding pharmacy may adjust pH during preparation; formulations differ between pharmacies; and the concentration a patient injects is not 10 g/L. So the honest statement is narrower than the one circulating online: the raw substance is acidic in solution, acidity is a well-established driver of injection pain, and that is a plausible and probably the leading explanation for the sting — but it is an inference about your specific vial, not a measurement of it.

If burning is a persistent problem, the pH of the preparation is a reasonable question to ask the prescribing clinician, who can ask the pharmacy directly. That is a more useful question than most of what gets asked about NAD+.

What about the flush, the chest tightness, and the cramping?

These are a different phenomenon from the local sting, and the pattern is well described by people using intravenous NAD+: abdominal cramping, nausea, a racing heart, chest pressure, and throat tightness during administration, resolving quickly once the rate is slowed or the infusion stops. A 2026 retrospective tolerability study in a real-world clinic setting documented this symptom cluster in patients receiving intravenous NAD+ (Reyna et al. 2026). It is a small, retrospective, non-randomised pilot — six patients in the NAD+ arm — so treat it as a careful description of what clinicians see, not as a dose-response finding. We cover the broader pattern of what users report in NAD+ injection side effects.

Rate appears to matter. In the best-characterised human pharmacokinetic study of intravenous NAD+, eight healthy men received a continuous six-hour infusion at roughly 2 mg per minute, and the authors reported no adverse events in either the NAD+ or the saline group (Grant et al. 2019). Slow and controlled produced nothing; faster administration in clinical practice reliably produces the symptom cluster above. That is consistent, though it has never been tested head-to-head as a rate comparison, which would be the study worth running.

For a subcutaneous injection the volumes are far smaller and this systemic picture is less relevant — but the same principle transfers. Going slowly is the single easiest variable a patient controls.

Does volume matter?

Less than people assume. A randomised crossover trial in healthy volunteers tested viscosity, volume and flow rate on subcutaneous injection tolerance and found that within the ranges tested — 2 mL versus 3 mL — volume and flow rate did not significantly change perceived pain, while higher viscosity was actually better tolerated than low (Berteau et al. 2015). The 2019 review notes that subcutaneous volumes up to roughly 1.5 mL are generally well tolerated, with more possible in the abdomen (Usach et al. 2019).

The practical read: if you are stinging, pH is a better hypothesis than volume.

What is worth adjusting, and what is worth escalating?

Technique changes that are reasonable to discuss with your prescribing clinician include injecting more slowly, letting a refrigerated vial come to room temperature before injecting, rotating sites, using a smaller-gauge needle, and — if the burn is persistent — asking whether the preparation can be pH-adjusted or the dose divided. Titration matters too. Starting lower and building is standard practice for exactly this class of tolerability problem, and it is the approach a supervised program should take by default — the same logic we walk through in NAD+ dosing and timing.

There is one reaction that is not a technique problem. In October 2024 the FDA issued a communication reminding compounders that some were using food-grade NAD+ raw material — sold by repackagers and not suitable for sterile compounding — and stated that it had received adverse event reports following use of injectable NAD+ drug products, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, consistent with excessive endotoxin levels (FDA 2024). That is a sourcing and sterility problem, not a pH problem, and it does not get fixed by injecting more slowly.

Rigors, fever, severe shaking, or vomiting after an NAD+ injection are not the expected sting. Stop, and contact your clinician. It is also the strongest reason to know which pharmacy compounds your medication — a question every patient is entitled to ask and every program should answer. If you are evaluating providers, how to vet an online longevity clinic covers what a straight answer looks like.

What does the evidence support beyond tolerability?

Being straight about this matters more than the marketing does. The most current systematic review of NAD+ for wellness and aging indications, covering 113 studies through October 2025, found no eligible outcomes trials evaluating intravenous or intramuscular NAD+ itself for those indications (Gallagher and Emmanuel 2026). Oral precursors reliably raise NAD-related biomarkers in the blood; the human functional outcomes across the literature are heterogeneous and often null.

So the honest framing of a tolerability question is this: we can explain the sting with reasonably solid pharmacology, and we can reduce it with reasonably ordinary clinical adjustments. That is a different and more modest claim than saying the injection is doing what the category promises. Both things can be true at once, and a patient deserves to hear both.

Bottom line

An NAD+ injection that burns is most plausibly explained by the acidity of the solution, and the variables a clinician can adjust are pH, rate, dose and site. Systemic symptoms during administration track with speed, and slowing down is the first move. Chills, shaking or vomiting are a different signal entirely and warrant a call rather than a technique change.

NAD+ is prescribed and compounded by a state-licensed, FDA-regulated compounding pharmacy. Compounded medications are not FDA-approved as finished products, and nothing here is a promise of results. This article is general education about a compounded medication — it is not medical advice, it is not a diagnosis, and it does not establish a clinician-patient relationship. Any decision about starting, adjusting or stopping an injectable medication belongs with your prescribing clinician.

NAD+ injection sting FAQ

Why does my NAD+ injection burn? Most plausibly the acidity of the solution: raw NAD+ in water has a reported pH of 2.5–3.0, and formulation pH is one of the strongest predictors of injection-site pain. Volume and speed contribute too — all three are modifiable.

Does the burning mean it’s working? No. The sting reflects the solution’s chemistry meeting tissue, not the medication’s biological activity — and on its own it is not evidence anything has gone wrong either.

How can I reduce the sting? Discuss with your prescribing clinician: inject more slowly, let the vial reach room temperature, rotate sites, use a smaller-gauge needle, divide the dose, or ask whether the preparation can be pH-adjusted.

Why do infusions cause flushing and chest tightness? That systemic cluster tracks with administration rate. Slowing down or pausing resolves it quickly in the published descriptions; a slow six-hour infusion produced no adverse events at all.

When should I stop and call? Rigors, fever, severe shaking or vomiting. The FDA has linked reactions like these to endotoxin from unsuitable raw material in some compounded products — a sourcing problem, not a technique problem.

Sources

Chief Medical Officer: Shannon Arora, MD

Shannon Arora, MD is the Chief Medical Officer of Trellis Vitality. This is a statement of role, not a review of this specific article.

Related reading